文献速递细菌感染、耐药与抗菌药物

新型双β-内酰胺联合方案对耐甲氧西林金黄色葡萄球菌的协同杀菌活性

Synergistic bactericidal activity of a novel dual β-lactam combination against methicillin-resistant Staphylococcus aureus.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

研究评估阿莫西林/头孢地尼双β-内酰胺联合方案对14株不同序列型MRSA的体外协同活性,并在大蜡螟幼虫感染模型中验证对USA300和COL株的体内疗效。棋盘试验显示所有菌株FICI<0.5且两药MIC均降低至少4倍,体内联合治疗使感染幼虫生存率提高至82%,与万古霉素疗效相当。

要点

  • 阿莫西林/头孢地尼对全部14株MRSA均显示协同活性,FICI<0.5。
  • 两药MIC均降低至少4倍,时间杀菌试验显示协同杀菌活性。
  • 感染幼虫接受联合治疗后生存率提高至82%,与万古霉素相当。

核心结论

  • 体外和体内研究提示阿莫西林/头孢地尼双联合对多种序列型的MRSA菌株具有协同杀菌效力。
  • 需要进一步研究探索其作为MRSA感染治疗选择的潜力。

研究设计与样本

  • 体外研究:采用棋盘法和时间杀菌试验检测阿莫西林/头孢地尼联合对14株代表性流行MRSA菌株(序列型多样)的活性。
  • 体内研究:采用大蜡螟幼虫感染模型评估该双联合对社区获得性MRSA菌株USA300和医院获得性MRSA菌株COL的疗效。

主要发现

  • 棋盘法显示阿莫西林/头孢地尼对全部受试MRSA菌株具有协同活性,FICI值低于0.5,两种抗生素的MIC均降低至少4倍。
  • 时间杀菌试验显示该双联合对MRSA菌株USA300和菌株COL具有协同杀菌活性。
  • 体内研究显示,给予感染MRSA菌株的大蜡螟幼虫阿莫西林/头孢地尼联合治疗,生存率显著提高至82%,与万古霉素疗效相当。

关键数值与推荐

  • 协同活性判定:FICI值低于0.5,且两种抗生素MIC均降低至少4倍。
  • 体内疗效:联合治疗使感染幼虫生存率提高至82%,与万古霉素疗效相当。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 需要进一步研究探索其作为MRSA感染治疗选择的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: MRSA is a major cause of hospital-acquired and community-acquired infections. Treatment options for MRSA are limited because of the rapid development of β-lactam resistance. Combining antibiotics offers an affordable, time-saving, viable and efficient approach for developing novel antimicrobial therapies. Both amoxicillin and cefdinir are oral β-lactams with indications for a wide range of bacterial infections and mild side effects. This study aimed to investigate the in vitro and in vivo efficacy of combining these two β-lactams against MRSA strains. METHODS: Fourteen representative prevalent MRSA strains with diverse sequence types (STs) were tested with a combination of amoxicillin and cefdinir, using chequerboard and time-kill assays. The Galleria mellonella larvae infection model was used to evaluate the in vivo efficacy of this dual combination against the community-acquired MRSA (CA-MRSA) strain USA300 and the hospital-acquired MRSA (HA-MRSA) strain COL. RESULTS: The chequerboard assay revealed a synergistic activity of the dual amoxicillin/cefdinir combination against all tested MRSA strains, with fractional inhibitory concentration index (FICI) values below 0.5 and at least a 4-fold reduction in the MICs of both antibiotics. Time-kill assays demonstrated synergistic bactericidal activity of this dual combination against the MRSA strain USA300 and strain COL. Moreover, in vivo studies showed that the administration of amoxicillin/cefdinir combination to G. mellonella larvae infected with MRSA strains significantly improved the survival rate up to 82%, which was comparable to the efficacy of vancomycin. CONCLUSIONS: In vitro and in vivo studies indicate that the dual combination of amoxicillin/cefdinir demonstrates a synergistic bactericidal efficacy against MRSA strains of various STs. Further research is needed to explore its potential as a treatment option for MRSA infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Altarawneh H, Alhomra T, Alharbi M, et al. Synergistic bactericidal activity of a novel dual β-lactam combination against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2024. PMID: 38831599. doi:10.1093/jac/dkae165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。